HRTX - Heron Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.59
+0.75 (+3.60%)
As of 11:06AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close20.84
Open21.05
Bid21.43 x 900
Ask21.48 x 900
Day's Range20.80 - 21.63
52 Week Range15.68 - 29.49
Volume380,682
Avg. Volume1,003,047
Market Cap2.014B
Beta (3Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Heron Therapeutics to Present at the Jefferies London Healthcare Conference

    SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 5:20 p.m. GMT (12:20 p.m. EST) at the Waldorf Hilton London hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

  • PR Newswire

    Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 8:35 a.m. EST at the Lotte New York Palace hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs.

  • PR Newswire

    Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

    - Heron Raises Full-Year 2019 CINV Franchise Net Product Sales Guidance from $115 -120 Million to $135 Million - SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage ...

  • PR Newswire

    Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

    SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain. The FDA set a PDUFA goal date of March 26, 2020.

  • PR Newswire

    Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

    SAN DIEGO , Oct. 22, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, Inc. following a class action complaint that was filed against Healthcare Services on March 22, 2019.

  • PR Newswire

    Heron Therapeutics Announces Pricing of Public Offering of Common Stock

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price of $17.50 per share.  In addition, Heron has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of its common stock on the same terms and conditions. The offering is expected to close on or about October 8, 2019, subject to customary closing conditions. The gross proceeds from the offering are expected to be approximately $150 million before deducting customary underwriting discounts and offering expenses.  Heron intends to use the proceeds from the proposed sale of its shares of common stock for the commercial launch of HTX-011, if approved by the U.S. Food and Drug Administration, the continued commercialization and marketing of SUSTOL® and CINVANTI®, Heron's ongoing and future clinical trials, including further clinical studies for HTX-011, preclinical development work, other product development activities and general corporate purposes.

  • PR Newswire

    Heron Therapeutics Announces Proposed Public Offering of Common Stock

    SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. Heron intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares sold in the public offering. All of the shares of common stock in the offering are to be sold by Heron.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

  • PR Newswire

    Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty

    - Mean Pain Scores Remain in Mild Range for 72 Hours following Surgery - - 75% of Patients Were Discharged without Opioids - SAN DIEGO , Oct. 2, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), ...

  • PR Newswire

    Heron Therapeutics Appoints Kimberly Manhard to Board of Directors

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Kimberly Manhard to Heron's Board of Directors. "I am pleased to welcome Kimberly to the Heron Board," said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron. "Kimberly has been a key member of our management team over the last 4 years and has been instrumental in driving the drug development and regulatory strategies for our pain and CINV franchises.

  • PR Newswire

    Heron Therapeutics Appoints Stephen Davis to Board of Directors

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Steve Davis to Heron's Board of Directors. "I am pleased to welcome Steve to the Heron Board," said Barry Quart, Pharm.D., President and Chief Executive Officer of Heron. "Steve's executive leadership in commercial organizations and public-company board of directors experience in the biopharmaceutical industry will be invaluable to Heron.

  • PR Newswire

    Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-011, an investigational agent for the management of postoperative pain. The Company anticipates a 6-month review by the FDA.

  • PR Newswire

    Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 2:25 p.m. EDT at the InterContinental New York Barclay hotel. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.

  • PR Newswire

    Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

    SAN DIEGO , Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • ACCESSWIRE

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, EGBN and CARB

    CEDARHURST, NY / ACCESSWIRE / August 5, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • PR Newswire

    Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019

    NEW YORK , Aug. 5, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. ("Heron" ...

  • ACCESSWIRE

    SHAREHOLDER ALERT: HRTX RBGLY JE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / August 5, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...

  • PR Newswire

    Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates

    SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

  • GlobeNewswire

    MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc. (“Heron” or “the Company”) (HRTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between October 31, 2018 and April 30, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before August 5, 2019. According to the Complaint, the Company made false and misleading statements to the market.

  • ACCESSWIRE

    CLASS ACTION UPDATE for HRTX, EROS and MNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / August 2, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...

  • GlobeNewswire

    Final Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019

    NEW YORK, Aug. 02, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron.

  • GlobeNewswire

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, STG, PVTL and GTT

    NEW YORK, Aug. 02, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.

  • GlobeNewswire

    Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. – HRTX

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Heron Therapeutics, Inc. (HRTX) from October 31, 2018 through April 30, 2019, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

  • ACCESSWIRE

    The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, RLGY and NFLX

    NEW YORK, NY / ACCESSWIRE / August 1, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.